Altered transcription factor trafficking in oxidatively-stressed neuronal cells

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 11, 2012, Pages 1773-1782

  Patel, Vivek P ^a,b   DeFranco, Donald B ^a,b   Chu, Charleen T ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

6 Hydroxydopamine; Microtubules; Nuclear trafficking; Oxidative stress; Parkinson's disease

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2;

ARTICLE; BRAIN NERVE CELL; CELL NUCLEUS; CELLULAR DISTRIBUTION; CYTOPLASM; NUCLEOCYTOPLASMIC TRANSPORT; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; UPREGULATION;

EID: 84865294854     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.08.002     Document Type: Article

References (112)

1. Courtney E., Kornfeld S., Janitz K., Janitz M. Transcriptome profiling in neurodegenerative disease. J. Neurosci. Methods 2010, 193:189-202.
2. Malaspina A., Kaushik N., de Belleroche J. Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J. Neurochem. 2001, 77:132-145.
3. Tanaka F., Niwa J., Ishigaki S., Katsuno M., Waza M., Yamamoto M., Doyu M., Sobue G. Gene expression profiling toward understanding of ALS pathogenesis. Ann. N. Y. Acad. Sci. 2006, 1086:1-10.
4. Calnan D.R., Brunet A. The FoxO code. Oncogene 2008, 27:2276-2288.
5. Chu C.T., Plowey E.D., Wang Y., Patel V., Jordan-Sciutto K.L. Location, location, location: altered transcription factor trafficking in neurodegeneration. J. Neuropathol. Exp. Neurol. 2007, 66:873-883.
6. Greene W.C., Chen L.F. Regulation of NF-kappaB action by reversible acetylation. Novartis Found. Symp. 2004, 259:208-217. (discussion 218-225).
7. Harreman M.T., Kline T.M., Milford H.G., Harben M.B., Hodel A.E., Corbett A.H. Regulation of nuclear import by phosphorylation adjacent to nuclear localization signals. J. Biol. Chem. 2004, 279:20613-20621.
8. Jans D.A., Xiao C.Y., Lam M.H. Nuclear targeting signal recognition: a key control point in nuclear transport?. Bioessays 2000, 22:532-544.
9. Kaspar J.W., Niture S.K., Jaiswal A.K. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic. Biol. Med. 2009, 47:1304-1309.
10. Patel V.P., Chu C.T. Nuclear transport, oxidative stress, and neurodegeneration. Int. J. Clin. Exp. Pathol. 2011, 4:215-229.
11. Sorokin A.V., Kim E.R., Ovchinnikov L.P. Nucleocytoplasmic transport of proteins. Biochemistry (Mosc.) 2007, 72:1439-1457.
12. Madan A.P., DeFranco D.B. Bidirectional transport of glucocorticoid receptors across the nuclear envelope. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:3588-3592.
13. Krug A.W., Pojoga L.H., Williams G.H., Adler G.K. Cell membrane-associated mineralocorticoid receptors? New evidence. Hypertension 2011, 57:1019-1025.
14. Revollo J.R., Cidlowski J.A. Mechanisms generating diversity in glucocorticoid receptor signaling. Ann. N. Y. Acad. Sci. 2009, 1179:167-178.
15. Watson C.S., Jeng Y.J., Kochukov M.Y. Nongenomic signaling pathways of estrogen toxicity. Toxicol. Sci. 2010, 115:1-11.
16. Samarasinghe R.A., Di Maio R., Volonte D., Galbiati F., Lewis M., Romero G., DeFranco D.B. Nongenomic glucocorticoid receptor action regulates gap junction intercellular communication and neural progenitor cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:16657-16662.
17. Chalovich E.M., Zhu J.H., Caltagarone J., Bowser R., Chu C.T. Functional repression of cAMP response element in 6-hydroxydopamine-treated neuronal cells. J. Biol. Chem. 2006, 281:17870-17881.
18. Ramsey C.P., Glass C.A., Montgomery M.B., Lindl K.A., Ritson G.P., Chia L.A., Hamilton R.L., Chu C.T., Jordan-Sciutto K.L. Expression of Nrf2 in neurodegenerative diseases. J. Neuropathol. Exp. Neurol. 2007, 66:75-85.
19. Yamada T., Yoshiyama Y., Kawaguchi N. Expression of activating transcription factor-2 (ATF-2), one of the cyclic AMP response element (CRE) binding proteins, in Alzheimer disease and non-neurological brain tissues. Brain Res. 1997, 749:329-334.
20. Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., McCluskey L.F., Miller B.L., Masliah E., Mackenzie I.R., Feldman H., Feiden W., Kretzschmar H.A., Trojanowski J.Q., Lee V.M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
21. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., Jenner P., Marsden C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 1989, 52:381-389.
22. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:2696-2701.
23. Moreira P.I., Nunomura A., Nakamura M., Takeda A., Shenk J.C., Aliev G., Smith M.A., Perry G. Nucleic acid oxidation in Alzheimer disease. Free Radic. Biol. Med. 2008, 44:1493-1505.
24. Nunomura A., Castellani R.J., Zhu X., Moreira P.I., Perry G., Smith M.A. Involvement of oxidative stress in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2006, 65:631-641.
25. Browne S.E., Beal M.F. Oxidative damage in Huntington's disease pathogenesis. Antioxid. Redox Signal. 2006, 8:2061-2073.
26. Barber S.C., Shaw P.J. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic. Biol. Med. 2010, 48:629-641.
27. Alam Z.I., Daniel S.E., Lees A.J., Marsden D.C., Jenner P., Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 1997, 69:1326-1329.
28. Floor E., Wetzel M.G. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem. 1998, 70:268-275.
29. Alam Z.I., Jenner A., Daniel S.E., Lees A.J., Cairns N., Marsden C.D., Jenner P., Halliwell B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 1997, 69:1196-1203.
30. Nakabeppu Y., Tsuchimoto D., Yamaguchi H., Sakumi K. Oxidative damage in nucleic acids and Parkinson's disease. J. Neurosci. Res. 2007, 85:919-934.
31. Shimura-Miura H., Hattori N., Kang D., Miyako K., Nakabeppu Y., Mizuno Y. Increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease. Ann. Neurol. 1999, 46:920-924.
32. Tan E.K., Skipper L.M. Pathogenic mutations in Parkinson disease. Hum. Mutat. 2007, 28:641-653.
33. Pridgeon J.W., Olzmann J.A., Chin L.S., Li L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol. 2007, 5:e172.
34. Liou A.K., Leak R.K., Li L., Zigmond M.J. Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway. Neurobiol. Dis. 2008, 32:116-124.
35. Drechsel D.A., Patel M. Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease. Free Radic. Biol. Med. 2008, 44:1873-1886.
36. Kulich S.M., Horbinski C., Patel M., Chu C.T. 6-Hydroxydopamine induces mitochondrial ERK activation. Free Radic. Biol. Med. 2007, 43:372-383.
37. Andrew R., Watson D.G., Best S.A., Midgley J.M., Wenlong H., Petty R.K. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem. Res. 1993, 18:1175-1177.
38. Linert W., Jameson G.N. Redox reactions of neurotransmitters possibly involved in the progression of Parkinson's Disease. J. Inorg. Biochem. 2000, 79:319-326.
39. Zhu J.H., Kulich S.M., Oury T.D., Chu C.T. Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases. Am. J. Pathol. 2002, 161:2087-2098.
40. Dagda R.K., Zhu J., Kulich S.M., Chu C.T. Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease. Autophagy 2008, 4:770-782.
41. Stevenson A.S., Cartin L., Wellman T.L., Dick M.H., Nelson M.T., Lounsbury K.M. Membrane depolarization mediates phosphorylation and nuclear translocation of CREB in vascular smooth muscle cells. Exp. Cell Res. 2001, 263:118-130.
42. Breitfeld P.P., McKinnon W.C., Mostov K.E. Effect of nocodazole on vesicular traffic to the apical and basolateral surfaces of polarized MDCK cells. J. Cell Biol. 1990, 111:2365-2373.
43. Zhu J.H., Horbinski C., Guo F., Watkins S., Uchiyama Y., Chu C.T. Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. Am. J. Pathol. 2007, 170:75-86.
44. Carey K.L., Richards S.A., Lounsbury K.M., Macara I.G. Evidence using a green fluorescent protein-glucocorticoid receptor chimera that the Ran/TC4 GTPase mediates an essential function independent of nuclear protein import. J. Cell Biol. 1996, 133:985-996.
45. Heitzer M.D., Wolf I.M., Sanchez E.R., Witchel S.F., DeFranco D.B. Glucocorticoid receptor physiology. Rev. Endocr. Metab. Disord. 2007, 8:321-330.
46. Yang J., Liu J., DeFranco D.B. Subnuclear trafficking of glucocorticoid receptors in vitro: chromatin recycling and nuclear export. J. Cell Biol. 1997, 137:523-538.
47. Przedborski S., Ischiropoulos H. Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease. Antioxid. Redox Signal. 2005, 7:685-693.
48. Munck A., Foley R. Kinetics of glucocorticoid-receptor complexes in rat thymus cells. J. Steroid Biochem. Mol. Biol. 1976, 7:1117-1122.
49. Zipper L.M., Mulcahy R.T. The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. J. Biol. Chem. 2002, 277:36544-36552.
50. Zhang D.D., Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol. Cell. Biol. 2003, 23:8137-8151.
51. Huang H.C., Nguyen T., Pickett C.B. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J. Biol. Chem. 2002, 277:42769-42774.
52. Yu R., Lei W., Mandlekar S., Weber M.J., Der C.J., Wu J., Kong A.N. Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. J. Biol. Chem. 1999, 274:27545-27552.
53. Zipper L.M., Mulcahy R.T. Inhibition of ERK and p38 MAP kinases inhibits binding of Nrf2 and induction of GCS genes. Biochem. Biophys. Res. Commun. 2000, 278:484-492.
54. Rojo A.I., Sagarra M.R., Cuadrado A. GSK-3beta down-regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J. Neurochem. 2008, 105:192-202.
55. Calkins M.J., Johnson D.A., Townsend J.A., Vargas M.R., Dowell J.A., Williamson T.P., Kraft A.D., Lee J.M., Li J., Johnson J.A. The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid. Redox Signal. 2009, 11:497-508.
56. Velichkova M., Hasson T. Keap1 regulates the oxidation-sensitive shuttling of Nrf2 into and out of the nucleus via a Crm1-dependent nuclear export mechanism. Mol. Cell. Biol. 2005, 25:4501-4513.
57. Cox L.J., Hengst U., Gurskaya N.G., Lukyanov K.A., Jaffrey S.R. Intra-axonal translation and retrograde trafficking of CREB promotes neuronal survival. Nat. Cell Biol. 2008, 10:149-159.
58. Dvorak Z., Modriansky M., Pichard-Garcia L., Balaguer P., Vilarem M.J., Ulrichova J., Maurel P., Pascussi J.M. Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol. Pharmacol. 2003, 64:160-169.
59. Harrell J.M., Murphy P.J., Morishima Y., Chen H., Mansfield J.F., Galigniana M.D., Pratt W.B. Evidence for glucocorticoid receptor transport on microtubules by dynein. J. Biol. Chem. 2004, 279:54647-54654.
60. Gunawardena S., Goldstein L.S. Cargo-carrying motor vehicles on the neuronal highway: transport pathways and neurodegenerative disease. J. Neurobiol. 2004, 58:258-271.
61. Morfini G.A., Burns M., Binder L.I., Kanaan N.M., LaPointe N., Bosco D.A., Brown R.H., Brown H., Tiwari A., Hayward L., Edgar J., Nave K.A., Garberrn J., Atagi Y., Song Y., Pigino G., Brady S.T. Axonal transport defects in neurodegenerative diseases. J. Neurosci. 2009, 29:12776-12786.
62. Cartelli D., Ronchi C., Maggioni M.G., Rodighiero S., Giavini E., Cappelletti G. Microtubule dysfunction precedes transport impairment and mitochondria damage in MPP+-induced neurodegeneration. J. Neurochem. 2010, 115:247-258.
63. Chung C.Y., Koprich J.B., Siddiqi H., Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci. 2009, 29:3365-3373.
64. Gillardon F. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability-a point of convergence in parkinsonian neurodegeneration?. J. Neurochem. 2009, 110:1514-1522.
65. Ren Y., Liu W., Jiang H., Jiang Q., Feng J. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J. Biol. Chem. 2005, 280:34105-34112.
66. Crampton N., Kodiha M., Shrivastava S., Umar R., Stochaj U. Oxidative stress inhibits nuclear protein export by multiple mechanisms that target FG nucleoporins and Crm1. Mol. Biol. Cell 2009, 20:5106-5116.
67. Czubryt M.P., Austria J.A., Pierce G.N. Hydrogen peroxide inhibition of nuclear protein import is mediated by the mitogen-activated protein kinase, ERK2. J. Cell Biol. 2000, 148:7-16.
68. Kodiha M., Chu A., Matusiewicz N., Stochaj U. Multiple mechanisms promote the inhibition of classical nuclear import upon exposure to severe oxidative stress. Cell Death Differ. 2004, 11:862-874.
69. Kodiha M., Tran D., Morogan A., Qian C., Stochaj U. Dissecting the signaling events that impact classical nuclear import and target nuclear transport factors. PLoS One 2009, 4:e8420.
70. Kodiha M., Tran D., Qian C., Morogan A., Presley J.F., Brown C.M., Stochaj U. Oxidative stress mislocalizes and retains transport factor importin-alpha and nucleoporins Nup153 and Nup88 in nuclei where they generate high molecular mass complexes. Biochim. Biophys. Acta 2008, 1783:405-418.
71. Stochaj U., Rassadi R., Chiu J. Stress-mediated inhibition of the classical nuclear protein import pathway and nuclear accumulation of the small GTPase Gsp1p. FASEB J. 2000, 14:2130-2132.
72. Yasuda Y., Miyamoto Y., Saiwaki T., Yoneda Y. Mechanism of the stress-induced collapse of the Ran distribution. Exp. Cell Res. 2006, 312:512-520.
73. Carpentier R., Sacchetti P., Segard P., Staels B., Lefebvre P. The glucocorticoid receptor is a co-regulator of the orphan nuclear receptor Nurr1. J. Neurochem. 2008, 104:777-789.
74. Kurkowska-Jastrzebska I., Litwin T., Joniec I., Ciesielska A., Przybylkowski A., Czlonkowski A., Czlonkowska A. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Int. Immunopharmacol. 2004, 4:1307-1318.
75. Le W., Conneely O.M., He Y., Jankovic J., Appel S.H. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J. Neurochem. 1999, 73:2218-2221.
76. Le W.D., Xu P., Jankovic J., Jiang H., Appel S.H., Smith R.G., Vassilatis D.K. Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet. 2003, 33:85-89.
77. Marchetti B., Serra P.A., Tirolo C., L'Episcopo F., Caniglia S., Gennuso F., Testa N., Miele E., Desole S., Barden N., Morale M.C. Glucocorticoid receptor-nitric oxide crosstalk and vulnerability to experimental parkinsonism: pivotal role for glia-neuron interactions. Brain Res. Rev. 2005, 48:302-321.
78. Marinelli M., Aouizerate B., Barrot M., Le Moal M., Piazza P.V. Dopamine-dependent responses to morphine depend on glucocorticoid receptors. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:7742-7747.
79. Ojeda V., Fuentealba J.A., Galleguillos D., Andres M.E. Rapid increase of Nurr1 expression in the substantia nigra after 6-hydroxydopamine lesion in the striatum of the rat. J. Neurosci. Res. 2003, 73:686-697.
80. Philips A., Maira M., Mullick A., Chamberland M., Lesage S., Hugo P., Drouin J. Antagonism between Nur77 and glucocorticoid receptor for control of transcription. Mol. Cell. Biol. 1997, 17:5952-5959.
81. Piazza P.V., Rouge-Pont F., Deroche V., Maccari S., Simon H., Le Moal M. Glucocorticoids have state-dependent stimulant effects on the mesencephalic dopaminergic transmission. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:8716-8720.
82. Sleiman P.M., Healy D.G., Muqit M.M., Yang Y.X., Van Der Brug M., Holton J.L., Revesz T., Quinn N.P., Bhatia K., Diss J.K., Lees A.J., Cookson M.R., Latchman D.S., Wood N.W. Characterisation of a novel NR4A2 mutation in Parkinson's disease brain. Neurosci. Lett. 2009, 457:75-79.
83. Sousa K.M., Mira H., Hall A.C., Jansson-Sjostrand L., Kusakabe M., Arenas E. Microarray analyses support a role for Nurr1 in resistance to oxidative stress and neuronal differentiation in neural stem cells. Stem Cells 2007, 25:511-519.
84. Le W., Pan T., Huang M., Xu P., Xie W., Zhu W., Zhang X., Deng H., Jankovic J. Decreased NURR1 gene expression in patients with Parkinson's disease. J. Neurol. Sci. 2008, 273:29-33.
85. Liu H., Wei L., Tao Q., Deng H., Ming M., Xu P., Le W. Decreased NURR1 and PITX3 gene expression in Chinese patients with Parkinson's disease. Eur. J. Neurol. 2012, 19:870-875.
86. Murer M.G., Dziewczapolski G., Menalled L.B., Garcia M.C., Agid Y., Gershanik O., Raisman-Vozari R. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol. 1998, 43:561-575.
87. Stephenson D.T., Childs M.A., Li Q., Carvajal-Gonzalez S., Opsahl A., Tengowski M., Meglasson M.D., Merchant K., Emborg M.E. Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys. Cell Transplant. 2007, 16:229-244.
88. Tillerson J.L., Caudle W.M., Reveron M.E., Miller G.W. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp. Neurol. 2002, 178:80-90.
89. Vernier P., Moret F., Callier S., Snapyan M., Wersinger C., Sidhu A. The degeneration of dopamine neurons in Parkinson's disease: insights from embryology and evolution of the mesostriatocortical system. Ann. N. Y. Acad. Sci. 2004, 1035:231-249.
90. Wilson J.M., Levey A.I., Rajput A., Ang L., Guttman M., Shannak K., Niznik H.B., Hornykiewicz O., Pifl C., Kish S.J. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996, 47:718-726.
91. Howells D.W., Porritt M.J., Wong J.Y., Batchelor P.E., Kalnins R., Hughes A.J., Donnan G.A. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp. Neurol. 2000, 166:127-135.
92. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H., Nagatsu T. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci. Lett. 1999, 270:45-48.
93. Nagatsu T., Mogi M., Ichinose H., Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J. Neural Transm. Suppl. 2000, 277-290.
94. Parain K., Murer M.G., Yan Q., Faucheux B., Agid Y., Hirsch E., Raisman-Vozari R. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. Neuroreport 1999, 10:557-561.
95. Roth D.M., Moseley G.W., Pouton C.W., Jans D.A. Mechanism of microtubule-facilitated "fast track" nuclear import. J. Biol. Chem. 2011, 286:14335-14351.
96. Davison A.J., Legault N.A., Steele D.W. Effect of 6-hydroxydopamine on polymerization of tubulin. Protection by superoxide dismutase, catalase, or anaerobic conditions. Biochem. Pharmacol. 1986, 35:1411-1417.
97. Lee C.F., Liu C.Y., Hsieh R.H., Wei Y.H. Oxidative stress-induced depolymerization of microtubules and alteration of mitochondrial mass in human cells. Ann. N. Y. Acad. Sci. 2005, 1042:246-254.
98. Smyth J.W., Hong T.T., Gao D., Vogan J.M., Jensen B.C., Fong T.S., Simpson P.C., Stainier D.Y., Chi N.C., Shaw R.M. Limited forward trafficking of connexin 43 reduces cell-cell coupling in stressed human and mouse myocardium. J. Clin. Invest. 2010, 120:266-279.
99. Tomlinson D.R., Bennett T. Fluorescence histochemical and ultrastructural observations on preterminal noradrenergic axons following ligation or treatment with 6-hydroxydopamine. Med. Biol. 1979, 57:39-47.
100. Landino L.M., Hasan R., McGaw A., Cooley S., Smith A.W., Masselam K., Kim G. Peroxynitrite oxidation of tubulin sulfhydryls inhibits microtubule polymerization. Arch. Biochem. Biophys. 2002, 398:213-220.
101. Mellon M.G., Rebhun L.I. Sulfhydryls and the in vitro polymerization of tubulin. J. Cell Biol. 1976, 70:226-238.
102. Landino L.M., Moynihan K.L., Todd J.V., Kennett K.L. Modulation of the redox state of tubulin by the glutathione/glutaredoxin reductase system. Biochem. Biophys. Res. Commun. 2004, 314:555-560.
103. Akhmanova A., Steinmetz M.O. Tracking the ends: a dynamic protein network controls the fate of microtubule tips. Nat. Rev. Mol. Cell Biol. 2008, 9:309-322.
104. Galjart N. Plus-end-tracking proteins and their interactions at microtubule ends. Curr. Biol. 2010, 20:R528-R537.
105. van der Vaart B., Akhmanova A., Straube A. Regulation of microtubule dynamic instability. Biochem. Soc. Trans. 2009, 37:1007-1013.
106. Janke C., Kneussel M. Tubulin post-translational modifications: encoding functions on the neuronal microtubule cytoskeleton. Trends Neurosci. 2010, 33:362-372.
107. Fukushima N., Furuta D., Hidaka Y., Moriyama R., Tsujiuchi T. Post-translational modifications of tubulin in the nervous system. J. Neurochem. 2009, 109:683-693.
108. Miyamoto Y., Saiwaki T., Yamashita J., Yasuda Y., Kotera I., Shibata S., Shigeta M., Hiraoka Y., Haraguchi T., Yoneda Y. Cellular stresses induce the nuclear accumulation of importin alpha and cause a conventional nuclear import block. J. Cell Biol. 2004, 165:617-623.
109. Wagstaff K.M., Jans D.A. Importins and beyond: non-conventional nuclear transport mechanisms. Traffic 2009, 10:1188-1198.
110. Forwood J.K., Lam M.H., Jans D.A. Nuclear import of Creb and AP-1 transcription factors requires importin-beta 1 and Ran but is independent of importin-alpha. Biochemistry 2001, 40:5208-5217.
111. Freedman N.D., Yamamoto K.R. Importin 7 and importin alpha/importin beta are nuclear import receptors for the glucocorticoid receptor. Mol. Biol. Cell 2004, 15:2276-2286.
112. Theodore M., Kawai Y., Yang J., Kleshchenko Y., Reddy S.P., Villalta F., Arinze I.J. Multiple nuclear localization signals function in the nuclear import of the transcription factor Nrf2. J. Biol. Chem. 2008, 283:8984-8994.